Chris Tame
Chief Executive Officer Ternary Therapeutics
Seminars
Thursday 30th October 2025
Panel Discussion: Beyond CRBN & VHL: Harnessing Novel Ligases for Next-Gen Drug Discovery
11:00 am
- What criteria and validation strategies should be used to determine whether a novel E3 ligase is suitable for therapeutic development?
- In what ways do novel ligases offer functional or pharmacological advantages over traditional ligases like CRBN or VHL?
- How can we build a compelling case—biologically and commercially—for prioritizing a novel ligase over established workhorses in drug development pipelines?
Thursday 30th October 2025
Chair’s Opening Remarks
9:00 am
Thursday 30th October 2025
Chair’s Closing Remarks
3:30 pm
Wednesday 29th October 2025
Building A Computational Design Platform For Any Molecular Glue
12:30 pm
- Discussing the requirements of a successful molecular glue design platform
- Blending the speed and scalability of Machine Learning with the accuracy of Physics-Based Methods for optimal protein-protein matching and ternary complex structure prediction
- Computational design and experimental validation of optimised molecular glue degraders and activators
